Agenus spikes on positive data for its brain cancer vaccine

July 1, 2014 2:45 PM

5
0

Agenus' ($AGEN) vaccine for a deadly form of brain cancer helped extend patients' lives in a single-arm study, the company said, news that sent its shares up as much as 20% on hopes it can find a partner to help it into Phase III.

In the Phase II study, which had no control arm, adding Agenus' Prophage vaccine to the standard of care led to a median overall survival of about 24 months in patients with newly diagnosed glioblastoma multiforme (GBM), the company said, and half of the study's 46 participants survived for two year...